|Year : 2015 | Volume
| Issue : 3 | Page : 283-285
Diffuse skeletal metastasis and low thyroglobulin level in a pediatric patient with papillary thyroid carcinoma
Seyed Rasoul Zakavi1, Narjess Ayati1, Jamshid Farahati2, Behrooz Davachi3
1 Nuclear Medicine Research Center, Ghaem Hospital, Mashhad University of Medical Sciences, Mashhad, Iran
2 Thyroid Center and Clinic for Radiology and Nuclear Medicine, St. Elisabeth Hospital, Dorsten, Germany
3 Department of Radiology, Ghaem Hospital, Mashhad University of Medical Sciences, Mashhad, Iran
|Date of Web Publication||11-Jun-2015|
Nuclear Medicine Research Center, Ghaem Hospital, Ahmadabad Ave., Mashhad
Source of Support: None, Conflict of Interest: None
| Abstract|| |
Thyroglobulin (Tg) is frequently measured in follow-up of patients with differentiated thyroid carcinoma. A low stimulated Tg level (<1 ng/ml) associated with normal neck ultrasonography is considered as the most reliable criteria for complete remission in low risk patients. We are reporting a case of pediatric thyroid cancer with diffuse skeletal metastasis associated with low serum Tg level bringing a point of caution in evaluation of patients with low Tg.
Keywords: Bone metastasis, papillary, thyroglobulin, thyroid cancer, whole body iodine scans
|How to cite this article:|
Zakavi SR, Ayati N, Farahati J, Davachi B. Diffuse skeletal metastasis and low thyroglobulin level in a pediatric patient with papillary thyroid carcinoma. Indian J Nucl Med 2015;30:283-5
|How to cite this URL:|
Zakavi SR, Ayati N, Farahati J, Davachi B. Diffuse skeletal metastasis and low thyroglobulin level in a pediatric patient with papillary thyroid carcinoma. Indian J Nucl Med [serial online] 2015 [cited 2021 May 13];30:283-5. Available from: https://www.ijnm.in/text.asp?2015/30/3/283/158550
| Introduction|| |
Thyroglobulin (Tg) is excreted exclusively by thyroid cells and is one of the key factors in the follow-up of patients with follicular differentiated thyroid carcinoma (FDTC). While lymph node metastasis may be associated with low Tg levels, the highest level of Tg is seen in bone metastasis. The sensitivity of Tg is very high for detection of bone metastasis especially after thyroid stimulating hormone (TSH) stimulation. Low Tg associated with normal neck ultrasonography is reported to have a very high negative predictive value for persistent disease and is used in many clinical trials as a proof of patient response to treatment. We are reporting a patient with diffuse skeletal metastasis associated with low serum Tg level bringing a point of caution in evaluation of patients with low Tg.
| Case report|| |
A 23-year-old man presented to our thyroid cancer clinic on May 2006 with a history of papillary thyroid carcinoma (PTC). He was operated about 10 years ago with no follow-up and no radio-iodine therapy. Primary pathology was PTC in a 4.5 cm × 4.0 cm × 3.0 cm nodule in the right thyroid lobe. The stage of the disease at the time of diagnosis was considered pT3NxMx. On presentation, he had no symptoms and neck examination revealed a small 1 cm mass in the thyroid bed in midline. He underwent repeat neck exploration, and pathology examination revealed adenomatous nodule.
Following discontinuation of Levothyroxine for 4 weeks, thyroid values were measured in the serum and TSH was 150 mIU/L, Tg level was 3.5 ng/ml and anti-Tg antibody level was 11 IU/ml. The BIOCODE (S.A, Liege, Belgium) kit was used for determination of Tg level with a sensitivity of 0.35 ng/ml and an inter assay variation of 4.8% and between assay variation of 6.1%. After 2007, Tg measurements were done using Elecsys_electrochemiluminescent immunoassay from Roche Diagnostics (Meylan, France). Anti-Tg antibody was measured using ELISA method (Trinity-Biotech) before 2007 and by Elecsys electrochemiluminescent immunoassay from Roche Diagnostics (Meylan, France) after 2007. Diagnostic whole body iodine scan was performed 2 days after administration of 74 MBq I-131 and widespread bone metastasis, regional lymph node metastasis, and thyroid bed uptake was detected [Figure 1]. Patient had no complaint and after asking him about any bone pain, remembered just occasional mild low back pain.
|Figure 1: Postablation whole body iodine scan (anterior and posterior views) performed 7 days after 7400 MBq of I-131 shows multiple areas of iodine uptake in the skull, sternum, thyroid bed, cervical spine, left clavicle, thoracic spine, lumbar spine, pelvis and left femoral diaphysis|
Click here to view
The patient was treated with 7400 MBq of 131-iodine. Postablation whole body iodine scan (WBIS) was identical to diagnostic WBIS. Suppressive therapy was started, and measurement of Tg was done after discontinuation of the drugs 8 months later. TSH level was 380 mIU/ml with simultaneous Tg level of 6 ng/ml and anti-Tg antibody level of 11 IU/ml. Treatment was repeated with another dose of 7400 MBq of I-131. Postablation whole body iodine scan again showed multiple foci of metastases with no significant change compared with the previous scan. Radiography of the pelvis showed a small lytic lesion in the iliac bone with a rim of sclerosis [Figure 2]a].
|Figure 2: (a) Pelvic radiography shows lytic lesion in the right iliac bone with a rim of sclerosis. (b) Computed tomography scan image from 2nd lumbar spine shows a lytic lesion in vertebral body with sclerotic rim and internal septa. Mild expansion also is noted. These findings strongly suggest low grade malignant lesion|
Click here to view
Since that time, the patient has been treated 5 more times with 131 I (total accumulated dose 51.8 GBq I-131). Tg level was always below 6 ng/ml in spite of multiple bone metastases. Thoraco-lumbar computed tomography scan was done for more confirmation and indicated the presence of skeletal involvement corresponding to the lytic lesions detected in the radiographies [Figure 2]b]. The patient underwent surgical biopsy from the lumbar spine (L2) and the pathology result was positive for metastatic carcinoma. Immunohistochemistry of the removed tissue was positive for thyroid transcription factor-1 and Tg markers in tumoral cells, confirming thyroid origin of the lesions [Figure 3].
|Figure 3: (a) Carcinoma cells with follicle-like structure formation (H and E, ×10). (b and c) immunohistochemistry study show positive cytoplasmic immunoreactivity for thyroglobulin. (d) Positive nuclear immunoreactivity for thyroid transcription factor-1|
Click here to view
| Discussion|| |
Thyroglobulin is frequently measured in follow-up of patients with FDTC. A low stimulated Tg level (<1 ng/ml) associated with normal neck ultrasonography is considered as the most reliable criteria for complete remission in low risk patients. Also stimulated Tg between 1 and 10 ng/ml concomitant with normal neck ultrasonography is considered as "acceptable response."  However false negative Tg in the presence of metastasis is reported in 6.8% of patients, although most of the patients in this report had only lymph node metastasis and only one patient had bone metastasis.  Another study in 194 patients with differentiated thyroid carcinoma (DTC), with a mean follow-up of 7.7 years found persistent disease in 1.5% of the patients. In that study, there was no patient with low serum Tg level concomitant with distant metastasis. 
Low Tg may be seen with poorly differentiated carcinoma or nonimmunoreactive Tg.  Falsely low or high Tg level is also reported in the presence of heterophile antibodies in serum of the patient. In our study Tg was measured with two different techniques and showed persistently low Tg and anti-Tg level throughout the years of follow-up.
In the present patient, inappropriate low serum Tg level in the presence of widespread skeletal metastases was noted in spite of measurement of Tg with two different kits and controlling for heterophile antibodies. Only few cases of skeletal metastases associated with low Tg level was reported in the literature, and only one of the reported cases had diffuse skeletal metastases.  Our patient brings more caution in definition of response as low Tg and normal neck ultrasonography.
Our patient is a case of pediatric thyroid cancer, operated at the age of 13 years old. As distant metastases are more commonly seen in pediatric patients, diagnostic WBIS may be useful in these patients irrespective of the result of Tg or neck ultrasonography. Early recognition and radio-iodine therapy are mandatory in the majority of these patients to prevent long term morbidity and possibly to improve survival.
The other teaching point in our patient is absence of symptoms in spite of widespread skeletal metastasis. This finding again emphasis on careful scrutiny in patients with DTC and not relying only on Tg level and symptoms.
| Conclusion|| |
Low Tg level and absence of symptom does not exclude widespread skeletal metastases in patients with PTC.
| References|| |
Tuttle RM, Tala H, Shah J, Leboeuf R, Ghossein R, Gonen M, et al
. Estimating risk of recurrence in differentiated thyroid cancer after total thyroidectomy and radioactive iodine remnant ablation: Using response to therapy variables to modify the initial risk estimates predicted by the new American Thyroid Association staging system. Thyroid 2010;20:1341-9.
Park EK, Chung JK, Lim IH, Park do J, Lee DS, Lee MC, et al
. Recurrent/metastatic thyroid carcinomas false negative for serum thyroglobulin but positive by posttherapy I-131 whole body scans. Eur J Nucl Med Mol Imaging 2009;36:172-9.
Menéndez Torre E, López Carballo MT, Rodríguez Erdozáin RM, Forga Llenas L, Goñi Iriarte MJ, Barbería Layana JJ. Prognostic value of thyroglobulin serum levels and 131I whole-body scan after initial treatment of low-risk differentiated thyroid cancer. Thyroid 2004;14:301-6.
Zanotti-Fregonara P, Grassetto G, Hindié E, Rubello D. A low thyroglobulin level cannot be used to avoid adjuvant 131I therapy after thyroidectomy for thyroid carcinoma. Eur J Nucl Med Mol Imaging 2009;36:169-71.
Zhao CL, Qiu ZL, Chen LB, Yuan ZB, Luo QY. Sustained and diffuse 131I avid bone metastases with low thyroglobulin levels in a patient with papillary thyroid carcinoma. Clin Nucl Med 2013;38:375-7.
[Figure 1], [Figure 2], [Figure 3]